Malignant Carcinoid Tumor of the Rectum in a Patient With Psoriatic Arthritis Treated With Etanercept

Diego Adrianzen Herrera, Mahjabeen Haq, Nazia Hussain


The connection between malignancy risk and tumor necrosis factor alpha (TNFa) inhibitors is still a working field. Generally, less attention has been paid to their association with solid tumors compared to the mostly accepted risk for lymphoma. Etanercept is somewhat underrepresented compared to other drugs in the class and entities other than rheumatoid arthritis (RA) have not been widely included in large cohort studies exploring malignancy correlations. Nonetheless, lymphoma association to etanercept has been found in some series and many solid malignancies cases in the context of etanercept use for conditions other than RA have been described as single reports. We present the first described case of rectal carcinoid tumor developing after treatment with etanercept in a patient with psoriatic arthritis and explore the literature for evidence about the association between solid tumors and etanercept use in autoimmune diseases.

J Med Cases. 2015;6(9):389-392


Etanercept; Carcinoid; Psoriatic arthritis

Full Text: HTML PDF

Browse  Journals  


Journal of clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics






Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.